NCT05392582 MicroRNA Regulation of Chronic Inflammation During Aging
| NCT ID | NCT05392582 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Utah |
| Condition | Chronic Inflammation |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-11-12 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-11-12 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study enrolling healthy individuals aged 18-35 and 65y and older to determine the health of immune cells in the blood and how these cells create inflammation and effect health as we age. It is hoped that once the nature of this relationship has been discovered we can more effectively design therapies to reduce this inflammation. The enrollment goal is 40 participants. The study will occur over the course of 1 month which will include a screening visit and a second visit where the participants will undergo an oral glucose tolerance test, blood draws and leg strength \& exercise tests.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 - 35y; 65y and older 2. BMI: \<30 kg/m2 3. Ability to sign informed consent 4. For older participant group: Clinical Frailty Scale score \< 3 and Mini-Cog score \> 3 5. Good general medical health, ambulatory and in independent living setting Exclusion Criteria: * History of cardiovascular disease (e.g., CHF, CAD, MI, CVA) * History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted) * History of kidney disease or failure (CKD \> stage 4) * History of vascular disease * Uncontrolled hypertension - Elevated systolic pressure \>150 or a diastolic blood pressure \> 100 * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted) * Chronic anti-inflammatory medication use (≥ 2 weeks) within 4 weeks of enrollment * Chronic inflammatory conditions (e.g., Rheumatoid Arthritis, Crohn's, fibromyalgia, lupus, colitis) HIV, Hepatitis B and C * History of stroke with motor disability * A recent history (\<12 months) of GI bleed * History of liver disease or AST/ALT 2 times above the normal limit * History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) * Current smokers or current tobacco use * Current pregnancy as determined by positive pregnancy test * Any staff members who report directly to the principal investigators.
Contact & Investigator
Micah Drummond
PRINCIPAL INVESTIGATOR
The University of Utah
Frequently Asked Questions
Who can join the NCT05392582 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Inflammation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05392582 currently recruiting?
Yes, NCT05392582 is actively recruiting participants. Contact the research team at micah.drummond@hsc.utah.edu for enrollment information.
Where is the NCT05392582 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT05392582 clinical trial?
NCT05392582 is sponsored by University of Utah. The principal investigator is Micah Drummond at The University of Utah. The trial plans to enroll 40 participants.